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1018Objective: Statins might have pleiotropic effects, independent of their ability to reduce lipid levels. Recent data
have suggested that statins improve early survival and cardiovascular outcomes after coronary artery bypass
graft surgery. The effectiveness of statin therapy in normolipidemic cardiac surgery patients is as yet unclear.
Methods:We evaluated 3056 consecutive patients who had undergone cardiac surgery between April 2004 and
April 2009. Perioperative statin therapy was defined as continued treatment both before ( 6 months) and after
the index surgery (included as a discharge medication). Hyperlipidemia (HL) was defined as a total cholesterol
level greater than 200 mg/dL within 6 months before surgery. Four groups were analyzed: (1) statin-untreated
normolipidemic (NL, n¼ 1052); (2) statin-treated normolipidemic (NLþ, n¼ 206); (3) statin-untreated hyper-
lipidemic (HL, n¼ 638); and (4) statin-treated hyperlipidemic (HLþ, n¼ 1160) patients. Adjusted hazard ratios
accounted for the known preoperative cardiac risk factors. Mortality was ascertained by retrospective database
review and the Social Security Death Index.
Results: The mean follow-up was 2.2 years. The crude rate of 30-day mortality was 3.0% (32/1052), 0% (0/
206), 8.0% (51/638), and 0.7% (8/1160) for the NL, NLþ, HL, and HLþ groups, respectively. The overall
all-cause crude mortality rate was 9.6% (101/1052), 3.9% (8/206), 17.2% (110/638), and 6.5% (75/1160)
for the NL, NLþ, HL, and HLþ groups, respectively. Statin therapy for NL patients undergoing cardiac
surgery independently reduced the overall all-cause mortality (adjusted hazard ratio, 0.34; 95% confidence
interval, 0.16–0.71; P ¼ .004).
Conclusions: Perioperative statin therapy was associated with reduced mid-termmortality for patients undergo-
ing cardiac surgery, irrespective of their baseline lipid status. This clinical evidence suggests that the beneficial
effects of statins might extend beyond their lipid-lowering ability. (J Thorac Cardiovasc Surg 2010;140:1018-27)Earn CME credits at
http://cme.ctsnetjournals.orgStatins are powerful inhibitors of 3-hydroxyl-3-methylglu-
taryl-coenzyme A reductase, the key rate-limiting step in
cholesterol biosynthesis, thereby enhancing the synthesis
of low-density lipoprotein (LDL) receptors and resulting
in diminished LDL cholesterol levels.1 Their ease of use,
potent reduction of apo-B fractions, and proven clinical
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The Journal of Thoracic and Cardiovascular Surhave brought statins to the forefront of current lipid-
lowering regimens.2,3
The National Cholesterol Education Program Adult
Treatment Panel III Guidelines4 expanded on the appropri-
ate candidates for statin therapy to include high-risk patients
with coronary heart disease, acute coronary syndromes,
diabetes mellitus, and severe hypercholesterolemia. The
current recommendations have supported aggressive reduc-
tions in LDL cholesterol in patients with underlying cardio-
vascular disease or those with coronary equivalents. Statin
therapy has become a mainstay in the perioperative treat-
ment of patients undergoing cardiac surgery within the
past few years. In a meta-analysis of more than 30,000 pa-
tients, Liakopoulos and colleagues5 found that preoperative
statin therapy significantly reduced early postoperative
adverse outcomes in patients undergoing coronary artery
bypass grafting (CABG).
To better understand the LDL-dependent and LDL-
independent (‘‘pleiotropic’’) effects of statin therapy, the
baseline cholesterol levels must be considered in the context
of statin efficacy. Emerging data have pointed to the benefi-
cial effects of statins in patients with hyperlipidemia (HL)
undergoing cardiac surgery. Thielmann and colleagues6
found that patients with HL who were pretreated with statin
therapy were at a significantly lower risk of major earlygery c November 2010
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
HL ¼ hyperlipidemia
HR ¼ hazard ratio
ICU ¼ intensive care unit
JUPITER ¼ Justification for the Use of Statins in
Prevention: an Intervention Trial
Evaluating Rosuvastatin
LDL ¼ low-density lipoprotein
LOS ¼ length of stay
NL ¼ normolipidemia
NYHA ¼ New York Heart Association
OR ¼ odds ratio
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with HL without statin treatment. With the indications for
statin therapy expanding, an important subset population
with normal lipid levels are being treated with lipid-
lowering agents. It is biologically and theoretically plausible
that the usefulness of statin therapy in the perioperative pe-
riodmight also extend to normolipidemic (NL) patients. Sta-
tins might play a role in the acute modulation of operative
inflammation, thus improving short-term postoperative out-
comes.7-10 Statins have been shown to decrease high-
sensitivity C-reactive protein levels,11,12 an inflammatory
biomarker shown to predict future cardiovascular
events.13,14 Data from the Justification for the Use of
Statins in Prevention: an Intervention Trial Evaluating
Rosuvastatin (JUPITER) trial demonstrated that statins
significantly reduced the incidence of major adverse
cardiovascular events in patients with NL without
underlying coronary heart disease but with elevated C-
reactive protein levels.15 Furthermore, statins might exert
wide-ranging systemic effects on the vascular endothelium,
angiogenesis, and thrombus formation.16,17 In addition, in
this high-risk patient population, optimal control of LDL
cholesterol might be necessary for a favorable prognosis af-
ter cardiac surgery. LDL cholesterol represents a potentially
amenable risk factor that could dynamically alter the long-
term postoperative course. Consensus guidelines have con-
tinued to reduce the favorable target for LDL-lowering reg-
imens for all patient populations. Finally, previous studies
by Tabata and colleagues18 and Fedoruk and colleagues19
have shown that perioperative statin therapy improves the
postoperative outcomes in patients undergoing valvular heart
surgery, a population without underlying atherosclerotic
disease.
At present, the clinical data on the efficacy of statin ther-
apy in patients with normal lipid profiles undergoing car-
diac surgery are lacking. We thus sought to elucidate theThe Journal of Thoracic and Careffects of perioperative statin therapy on HL and NL pa-
tients undergoing cardiac surgery.
MATERIALS AND METHODS
Study Design
We used a retrospective cohort design and evaluated 3056 consecutive
patients (2007 men, 1049 women; aged 18 to 95 years) who had undergone
cardiac surgery at Northwestern Memorial Hospital between April 1, 2004
andApril 1, 2009. Data regarding statin usewas obtained from a prospectively
collected in-hospital surgical database; however, the data detailing the dosages
and types of statins used were not available. Because the effects of acute
changes in statin therapy during the hospital visit are unclear,20 we decided
to use amore conservative definition of statin therapy. Perioperative statin ther-
apywasdefinedas continued treatment bothbefore (at least 6months) andafter
the index surgery (included as a dischargemedication).HLwas definedas a to-
tal cholesterol level greater than 200 mg/dL within 6 months before surgery.
Using these definitions, 4 groups were analyzed: (1) statin-untreated NL
(NL, n ¼ 1052); (2) statin-treated NL (NLþ, n ¼ 206); (3) statin-untreated
HL (HL, n¼ 638); and (4) statin-treated HL (HLþ, n¼ 1160) patients. The
institutional review board of Northwestern Memorial Hospital reviewed and
approved the present study. All patients included in the study provided explicit
informed consent for the use of their medical records for research purposes.
Baseline Covariates
A retrospective database review was used to document the patient base-
line characteristics, including demographics (age, gender, race); clinical
characteristics (body mass index, current smoking status, severe comorbid-
ities, personal or family history of cardiovascular disease); surgical charac-
teristics (ejection fraction, preoperative creatinine, preoperative cardiogenic
shock, surgical indication), and concomitant medications (angiotensin-
converting enzyme inhibitors, clopidogrel, aspirin, b-blockers, warfarin).
Short-Term and Mid-Term Outcomes
Theprimaryoutcomeanalyzedwasall-cause andcardiac-relatedmortality,
including short-term and late survival (determined from the follow-up data).
The prespecified secondary outcomes measured were 30-day morbidity and
length of stay (LOS). All outcomeswere determined from the standard defini-
tions established by the Society of Thoracic Surgeons database:
1. 30-Daymortality included patients who had died during the hospital-
ization for the index procedure (even if the visit surpassed 30 days)
and those who had died after discharge from the hospital but within
30 days of their surgery.
2. Mid-term survival and the survival interval were ascertained using
the Social Security Death Index and retrospective chart review.
Patients were documented as alive if they were not listed in the
Social Security Death Index at the time of query (June 2009). The
cause of death was verified by retrospective database review and
was classified as either cardiac or noncardiac related.
3. 30-Day morbidity included myocardial infarction, cerebrovascular
accident, cardiac arrest, coma, and major bleeding episodes during
the postoperative hospitalization. These morbidity outcomes were
analyzed individually and as a composite postoperative endpoint.
4. Two measures of LOS were analyzed: the duration of the use of the
intensive care unit (ICU) after surgery and the entire length of the
hospital visit from admission to discharge.
Data on the postoperative events and late survival were available for all
patients included in the study cohort.Statistical Analysis
On the basis of the primary objective of the investigation, the effect of
statin therapy in NL and HL patients was analyzed separately. Because HLdiovascular Surgery c Volume 140, Number 5 1019
TABLE 1. Demographics and health characteristics
Characteristic
NL HL
No statins (n ¼ 1052) Statins (n ¼ 206) P value No statins (n ¼ 638) Statins (n ¼ 1160) P value
Demographic
Mean age (y) 57.7  16 64.1  12  .0001 64.7  12 66.0  11 .02
Male 622 (59.1) 151 (73.3)  .0001 410 (64.3) 824 (71.0) .003
Race/ethnicity
White 737 (70.1) 143 (69.4) 454 (71.2) 827 (71.3)
Black 102 (9.7) 22 (10.7) > .2 58 (9.1) 93 (8.0) > .2
Hispanic/other 213 (20.2) 41 (19.9) 126 (19.7) 240 (20.7)
Clinical
Body mass index (kg/m2) 26.8  6 28.7  6  .0001 28.2  6 28.6  6 > .2
Current smoker 271 (25.8) 75 (36.4) .002 224 (35.1) 390 (33.6) > .2
Diabetes 114 (10.8) 53 (25.7)  .0001 160 (25.1) 281 (24.2) > .2
Hypertension 444 (42.2) 132 (64.1)  .0001 461 (72.3) 849 (73.2) > .2
AF 293 (27.9) 38 (18.4) .005 153 (24.0) 210 (18.1) .003
CHF 316 (30.0) 62 (30.1) > .2 220 (34.5) 299 (25.8)  .0001
NYHA class
I 299 (28.4) 40 (19.4) 104 (16.3) 279 (24.1)
II 397 (37.7) 100 (48.5) .003 231 (36.2) 476 (41.0)  .0001
III 263 (25.0) 55 (26.7) 202 (31.7) 330 (28.4)
IV 92 (8.7) 10 (4.9) 101 (15.8) 75 (6.5)
Renal failure 48 (4.6) 9 (4.4) > .2 47 (7.4) 60 (5.2) .06
Previous dialysis 23 (2.2) 4 (1.9) > .2 21 (3.3) 27 (2.3) > .2
COPD 94 (8.9) 17 (8.3) > .2 94 (14.7) 136 (11.7) .07
PVD 54 (5.1) 15 (7.3) > .2 57 (8.9) 124 (10.7) > .2
Pulmonary hypertension .08  .0001
None 771 (73.3) 138 (67.0) 457 (71.6) 941 (81.1)
Moderate ( 35 mmHg) 190 (18.1) 51 (24.8) 104 (16.3) 153 (13.2)
Severe ( 50 mmHg) 91 (8.7) 17 (8.3) 77 (12.1) 66 (5.7)
Previous MI 72 (6.8) 51 (24.8)  .0001 155 (24.3) 330 (28.4) .06
Previous angina 167 (15.9) 78 (37.9)  .0001 215 (33.7) 443 (38.2) .06
Previous stroke/TIA 90 (8.6) 20 (9.7) > .2 76 (11.9) 177 (15.3) .05
Family history of CAD 157 (14.9) 37 (18.0) > .2 160 (25.1) 291 (25.1) > .2
Continuous variables are presented as mean  standard deviation and were compared between statin users and nonusers using 2-sided Student’s independent t test (with Sat-
terthwaite adjustment if variances were unequal). Categorical variables are presented as n (%) and were compared using c2 tests. AF, Atrial fibrillation; CHF, congestive heart
failure;NYHA,NewYork Heart Association;COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease;MI,myocardial infarction; TIA, transient ischemic
attack; CAD, coronary artery disease.
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the HL and NL patient cohorts. The baseline indexes were compared in the
statin users versus the statin nonusers (for both NL and HL patients). Con-
tinuous variables are presented as the mean standard deviation and were
compared using 2-sided Student’s independent t tests. The Satterthwaite
adjustment was used in cases of unequal variance. The categorical vari-
ables are expressed as frequencies and were compared using Pearson’s
c2 exact tests. Various multivariate techniques were used to determine
the independent contribution of perioperative statin therapy to outcome
measures, after adjusting for patient demographics, known preoperative
cardiac risk factors, surgical characteristics, and concomitant medications.
The primary outcome was analyzed using the Cox proportional hazards
model to calculate the hazards ratio (HR) and 95% confidence interval
(CI) to assess the differences in late survival after surgery between the sta-
tin users and nonusers and to identify significant independent predictors of
mid-term mortality. Schoenfeld residuals, correlated with time and partial
residual plots, were used to verify the validity of the proportional hazards
assumption. Kaplan-Meier survival curves were constructed and compared
using the log-rank test. Odds ratios (ORs) were determined from the logis-
tic regression analyses to compare the postoperative events (30-day mor-
bidity and mortality). Multiple regression analyses were performed to1020 The Journal of Thoracic and Cardiovascular Surevaluate the effect of statin use on the LOS (ICU and entire hospital visits).
Final adjusted models were created using a combination of forward and
backward selection procedures. Each baseline covariate listed in Tables 1
and 2 was evaluated individually in single-predictor models for the primary
and secondary outcomes. Themultivariate models included significant can-
didate predictors (P<.2) according to this bivariate screening. The final
multivariate models for the clinical endpoints were determined by stepwise
removal of the variables that were not significant (P>.05). All statistical
analyses were performed using STATA statistical software (StataCorp
LP, College Station, Tex).RESULTS
Baseline Risk Comparisons
The preoperative baseline characteristics of the 4 groups
defined by statin treatment and lipid status are listed in
Table 1. Of the 1258 NL patients (41.1%) included in the
study cohort, the statin users were more likely to be signif-
icantly older (by 6.4 years), be male, and have greater rates
of obesity and other known cardiac risk factors (ie,gery c November 2010
TABLE 2. Surgical characteristics and concomitant medications
Variable
NL HL
No statins (n ¼ 1052) Statins (n ¼ 206) P value No statins (n ¼ 638) Statins (n ¼ 1160) P value
Surgical characteristics
Ejection fraction (%) 53.4  14 52.7  13 > .2 50.4  16 51.9  14 .05
No. of diseased vessels 0.6  1 1.8  1  .0001 1.5  1 1.9  1  .0001
Left main disease 51 (4.8) 42 (20.4)  .0001 89 (13.9) 235 (20.3) .001
Preoperative creatinine 1.1  1 1.2  1 > .2 1.3  1 1.2  1 > .2
Preoperative cardiogenic
shock
38 (3.6) 8 (3.9) > .2 32 (5.0) 1.2 (1.2)  .0001
Surgery incidence
First cardiac surgery 877 (83.4) 180 (87.4) 495 (77.6) 974 (84.0)
Second cardiac surgery 150 (14.3) 21 (10.2) > .2 116 (18.2) 163 (14.1) .001
More than 2 cardiac
surgeries
25 (2.4) 5 (2.4) 27 (4.2) 23 (2.0)
Emergent/urgent 214 (20.3) 48 (23.3) > .2 181 (28.4) 259 (22.3) .001
Surgery type
CABG only 98 (9.3) 73 (35.4) 166 (26.0) 455 (39.2)
Valve only 675 (64.2) 57 (27.7)  .0001 234 (36.7) 320 (27.6)  .0001
CABGþvalve 121 (11.5) 48 (23.3) 145 (22.7) 255 (22.0)
Other cardiac 158 (15.0) 28 (13.6) 93 (14.6) 130 (11.2)
Concomitant medications
ACE inhibitors 328 (31.2) 68 (33.0) > .2 231 (36.2) 565 (48.7)  .0001
Clopidogrel 17 (1.6) 8 (3.9) .03 36 (5.6) 62 (5.3) > .2
Aspirin 228 (21.7) 98 (47.6)  .0001 264 (41.4) 584 (50.3)  .0001
b-Blockers 494 (47.0) 127 (61.7)  .0001 371 (58.2) 764 (65.9) .001
Warfarin 100 (9.5) 10 (4.9) .03 58 (9.1) 69 (5.9) .01
Continuous variables are presented as mean  standard deviation and were compared between statin users and nonusers using 2-sided Student’s independent t test (with Sat-
terthwaite adjustment if variances were unequal). Categorical variables are presented as n (%) and compared using c2 tests. CABG, Coronary artery bypass graft; ACE,
angiotensin-converting enzyme; ADP, adenosine diphosphate.
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Dsmoking, diabetes, hypertension). Statin users were more
than 3 times as likely to have experienced a previous myo-
cardial infarction and twice as likely to have experienced
episodes of angina than the NL population. Statin nonusers
were more likely to have greater rates of more advanced
New York Heart Association (NYHA) classes and atrial fi-
brillation. Of the 1798 HL patients (58.9%), similar, but
less pronounced, differences were observed at baseline be-
tween the statin users and nonusers. The perioperative statin
users were more likely to be older (by 1.3 years), be male
and have a had a previous stroke or transient ischemic at-
tach. Also, the HL, statin nonusers were more likely to
have an adverse NYHA class distribution, greater rates of
congestive heart failure, and more severe pulmonary hyper-
tension. Overall, race, comorbid renal or obstructive lung
disease, and family history of coronary disease did not sig-
nificantly differ across the 4 groups.
The surgical characteristics and concomitant medications
of the patients who were and were not pretreated with
statins are listed in Table 2. Of the NL patients, statin users
were more likely to have a greater number of diseased ves-
sels, left main disease, greater rates of CABG, and to be
concomitantly treated with clopidogrel, aspirin, and b-
blockers. In contrast, the NL, statin nonusers were more
likely to have undergone more valvular procedures and toThe Journal of Thoracic and Carreceive warfarin therapy. Similar findings were noted in
the HL cohort, except that the statin nonusers tended to
have more depressed ejection fractions and greater rates
of preoperative cardiogenic shock and were more likely to
present for repeat or urgent procedures.
Outcomes
From the adverse clinical risk profiles listed in Tables 1
and 2, the mortality and morbidity were expected to be
worse for the NL statin users. However, despite this, the
statin users consistently had better outcomes than the
nonusers in this population.
30-day mortality. For the NL cohort, statin therapy
effectively reduced the 30-day mortality rate to 0% (0/
206) for the NL patients taking statins compared with
3.0% (32/1052) for the NL statin nonusers (P ¼ .01,
Table 3).
For the HL cohort, as expected, perioperative statin ther-
apy also significantly reduced the 30-day mortality rate
(8.0% [51/638] vs 0.7% [8/1160]), with a univariate OR
of 0.08 (95% CI, 0.04–0.17; P  .0001). These differences
in early mortality persisted even after adjusting for the
significant baseline covariates (adjusted OR, 0.11; 95%
CI, 0.05–0.25; P  .0001), strongly favoring perioperative
statin therapy (Table 3).diovascular Surgery c Volume 140, Number 5 1021
TABLE 3. Univariate and multivariate logistic regression analyses for 30-day morbidity and mortality in normolipidemic and hyperlipidemic
patients undergoing cardiac surgery
Variable No statin use Statin use Univariate OR (95% CI) P value Risk-adjusted OR (95% CI) P value
NL patients 1052 (100) 206 (100)
30-d Mortality 32 (3.0) 0 (0.0) — .01 — —
30-d Combined morbidity 60 (5.7) 4 (1.9) 0.33 (0.12–0.91) .03 0.26 (0.09–0.80) .02
MI 14 (1.3) 1 (0.5) 0.36 (0.05–2.77) > .2 0.16 (0.02–1.49) .11
CVA 18 (1.7) 2 (1.0) 0.56 (0.13–2.44) > .2 0.66 (0.13–3.35) > .2
Cardiac arrest 32 (3.0) 1 (0.5) 0.16 (0.02–1.14) .07 0.10 (0.01–0.83) .03
Coma 7 (0.7) 0 (0.0) ––– > .2 ––– –––
Bleeding 7 (0.7) 0 (0.0) ––– > .2 ––– –––
HL patients 638 (100) 1160 (100)
30-d Mortality 51 (8.0) 8 (0.7) 0.08 (0.04–0.17)  .0001 0.11 (0.05–0.25)  .0001
30-d Combined morbidity 54 (8.5) 54 (4.7) 0.53 (0.36–0.78) .001 0.60 (0.39–0.92) .02
MI 8 (1.3) 16 (1.4) 1.10 (0.47–2.59) > .2 0.93 (0.38–2.25) > .2
CVA 17 (2.7) 19 (1.6) 0.58 (0.29–1.13) .11 0.76 (0.35–1.65) >0.2
Cardiac arrest 22 (3.4) 18 (1.6) 0.44 (0.23–0.83) .01 0.10 (0.01–0.83) .03
Coma 7 (1.1) 1 (0.1) 0.08 (0.01–0.63) .02 0.07 (0.01–0.69) .02
Bleeding 10 (1.6) 5 (0.4) 0.27 (0.09–0.80) .02 0.39 (0.12–1.28) .12
Outcome variables are presented as n (%). P values were determined by univariate and multivariate logistic regression analyses, except for outcomes with no events (which were
compared using Pearson’s c2 tests). NL, Normolipidemic; CI, confidence interval; OR, odds ratio; MI, myocardial infarction; CVA, cerebrovascular accident.
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26.2  16.9 months. The predictors of late survival in the
final model were distinct for the NL and HL groups.
For the NL cohort, the overall all-cause mortality rate
was 9.6% for the statin-untreated group and only 3.9% in
the statin-treated group. Univariate analysis of the primary
outcome showed that statin therapy significantly reduced
mid-term mortality (HR, 0.40; 95% CI, 0.19–0.82;
P ¼ .008). The strength of the association became even
stronger after adjusting for the adverse risk factors in the sta-
tin group. Perioperative statin therapy independently re-
duced the mid-term mortality (adjusted HR, 0.34; 95% CI,
0.16–0.71; P ¼ .004; Figure 1, A). Statin users also experi-
enced lower rates of cardiac death (3.3% vs 0.5%) and non-
cardiac death (6.3% vs 3.4%) when analyzed separately.
The significant reductions in cause-specific deathwere inde-
pendent of the underlying baseline risk indexes. The risk-
adjusted HR was 0.14 (95% CI, 0.02–1.00; P ¼ .05) for
cardiac-related mortality and 0.43 (95% CI, 0.19–0.98;
P ¼ .05) for noncardiac-related mortality (Figure 1, A).
Figure 2, A shows the significant predictors of all-cause
mid-term mortality in the fully adjusted Cox proportional
hazards model. For NL patients, perioperative statin therapy
and bodymass index remained protective factors against the
primary outcome. In contrast, perioperative warfarin ther-
apy, combination valve/CABG, advanced NYHA classes,
smoking, and age all increased the risk of all-causemortality.
For the HL cohort, statin therapy in the perioperative pe-
riod of cardiac surgery reduced the overall rate of all-cause
mortality from 17.2% for nonusers to 6.5% for statin users.
Statin users had consistently favorable mid-term mortality
outcomes compared with their nonuser counterparts. The
adjusted HR was 0.42 (95% CI, 0.31-0.57; P  .0001) for1022 The Journal of Thoracic and Cardiovascular Surall-cause mortality, 0.16 (95% CI, 0.08-0.34; P  .0001)
for cardiac-related death, and 0.52 (95% CI, 0.36-0.73;
P  .0001) for noncardiac-related death, robustly support-
ing perioperative statin use for HL patients (Figure 1, B).
Figure 2, B presents the significant independent predic-
tors of late survival for HL patients. Perioperative statin
therapy and gender (males) were inversely associated with
all-cause mortality. Perioperative warfarin therapy, a repeat
or an urgent procedure, preoperative cardiogenic shock,
preoperative creatinine level, severe pulmonary hyperten-
sion, advanced NYHA classes, and age all increased the
risk of death after cardiac surgery.
Finally, the Kaplan-Meier survival curves showed early
and continued separation of the mortality trends throughout
the follow-up period (P  .0001) (Figure 3). Statin use,
regardless of baseline lipid status, improved late survival.
HL and NL patients who were not pretreated with statins
had increased mortality compared with the 2 groups
receiving statin therapy.
30-day morbidity. Table 3 lists the postoperative nonfatal
adverse events for the NL and HL patients. Statin therapy
consistently reduced all major surgical complications for
NL patients, with a composite 30-day morbidity rate of
5.7% (60/1052) for nonusers compared with only 1.9%
(4/206) for statin users. Statin users did not experience
any coma or bleeding events in the early postoperative pe-
riod. The risk-adjusted OR for 30-day morbidity was 0.26
(95% CI, 0.09-0.80; P ¼ .02).
Statin therapy for theHL cohort also reduced awide range
ofmajor complications after cardiac surgery, with a compos-
ite 30-day morbidity rate of 8.5% (54/638) for nonusers
compared with almost one half that rate for statin users
(4.7%; 54/1160). Perioperative statin therapy independentlygery c November 2010
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FIGURE 1. Multivariate hazard ratios for primary outcome (late survival)
in A, normolipidemic (NL) and B, hyperlipidemic (HL) patients undergo-
ing cardiac surgery. HR, Hazard ratio; () statin, no statin therapy; (þ) sta-
tin, statin therapy.
A
B
FIGURE 2. Significant predictors of primary outcome (late survival, all-
cause mortality) in final Cox proportional hazards models in A, normolipi-
demic and B, hyperlipidemic patients undergoing cardiac surgery. CABG,
Coronary artery bypass graft; NYHA, New York Heart Association; BMI,
body mass index; HTN, hypertension.
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Dreduced the rates of 30-day morbidity events, with an
adjusted OR of 0.60 (95% CI, 0.39-0.92; P ¼ .02).
Length of stay (Figure 4). In the NL cohort, multiple
regression analysis demonstrated that statin therapy
reduced the LOS of the ICU visit and the total hospital visit.
Despite showing a trend in the right direction, the risk-
adjusted b coefficients were not significant.
In the HL cohort, statin therapy strongly reduced the ICU
component of the LOS by 1.6 days (95% CI,2.3 to0.9;
b coefficient,0.11; P  .0001) and the LOS of the entire
hospital visit by 1.7 days (95% CI,2.7 to0.8; b coeffi-
cient,0.07; P  .0001).DISCUSSION
This is first study to demonstrate that perioperative statin
therapy significantly reduces early, as well as late, cardio-
vascular events after cardiac surgery in NL patients. Statin
therapy in our study was shown to protect against 30-day
mortality, 30-day composite morbidity, and mid-term mor-The Journal of Thoracic and Cartality (all-cause, cardiac, and noncardiac mortality), inde-
pendently of the known preoperative cardiac risk factors.
Statin therapy reduced the 30-day mortality rate among
NL patients to 0% and more than halved the mid-term mor-
tality. Although statins reduced the postoperative LOS by
approximately 1 day, these results were not significant. Be-
cause statin therapy has been previously demonstrated to be
effective in patients with abnormal lipid profiles, the inclu-
sion of HL patients in our analytic cohort served as an inter-
nal control. As expected, perioperative statin therapy for HL
patients strongly reduced the incidence of short- and mid-
term adverse outcomes. Also, statin therapy reduced the
LOS during the ICU visit and the total hospital visit in
this population by more than 1.5 days. The latter finding
might be particularly important in the current healthcare
environment. Elevated LDL cholesterol levels have long
been recognized as an important risk factor for future car-
diovascular events and a worse prognosis after coronarydiovascular Surgery c Volume 140, Number 5 1023
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Dinterventions.21 It was thus surprising that the assessment of
long-term survival up to a mean follow-up of 2.2 years
showed that statin users had superior survival, regardless
of their baseline lipid status. These results support the initi-
ation of aggressive lipid-lowering therapy in patients under-
going cardiac surgery, without a primary regard of the lipid
status.
These findings from patients undergoing cardiac surgery
are informative for many reasons. A substantial number of2.6
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FIGURE 4. Multiple regression analyses predicting length of stay in intensive
demic patients undergoing cardiac surgery.
1024 The Journal of Thoracic and Cardiovascular Surstudies have supported perioperative treatment of patients
undergoing CABG.22 A recent meta-analysis, summarizing
the findings from 19 studies (including 3 randomized con-
trolled trials), confirmed the beneficial effects of statin ther-
apy for this surgical population from the pooled data.5 It is
difficult, however, to determine whether this apparent cardi-
oprotection is garnered from lipid-dependent or lipid-
independent effects. Thielmann and colleagues6 were the
first to attempt to clinically approach this issue by assessing9.2
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care unit (ICU) and total hospital visit for normolipidemic and hyperlipi-
gery c November 2010
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Dthe statin treatment effects on short-term outcomes among
HL patients. The investigators defined HL similar to the def-
inition used in our study, but they defined all patients who
had had pretreatment with statins as having had abnormal
lipid profiles. Since the publication of their work in a previ-
ous issue of the Journal,6 the indications for statin therapy
have continued to expand.We began to observe a previously
unrecognized emergent subset population in our surgical se-
ries of patients. NL patients who were perioperatively
treated with statins represented a relatively small fraction
(16.4%) of all NL patients presenting for cardiac surgery
in our study. These patients, however, experienced the best
outcomes across all groups analyzed, despite being older
and having greater rates of comorbid disease. Our unique
study design that included 4 groups of patients stratified by
baseline lipid level and treatment status allowed for a more
definitive approach to the question of LDL-independent
(pleiotropic) and LDL-dependent statin actions.
Althoughwewere unable tomechanistically assess the ef-
fects of statin therapy on the cardiac and systemic biology,
our results have provided clinical data that cardioprotection
with statins extends beyond their lipid-lowering capacity.
The results from our surgical series have demonstrated an
early, pronounced reduction in events that might not be ade-
quately explained by the alterations in cardiac risk conferred
byLDL reduction alone. Surgery requiring cardiopulmonary
bypass acutely creates a pro-inflammatory state,with accom-
panyingmarkedmyocardial necrosis.23,24 Statinsmight play
a unique role inmodulating this inflammatorymilieu, tipping
the balance in favor of recovery.7-10 Furthermore, the
therapeutic effects of statins might continue to be apparent
even outside the operating room. Some of the effects not
directly related to LDL reduction include physiologic
changes in endothelial function, coagulation, platelet
activation, smooth muscle responsiveness, inflammatory
cell function, and thrombus stability.16,17 Our findings of
early and late reduction in morbidity and mortality with
statin therapy could be explained by these pleiotropic effects.
A few key limitations should be recognized regarding the
present study. First and foremost, a major limitation was the
retrospective, nonrandomized study design. Considerable
baseline differences were present between the statin users
and nonusers that made our final interpretation of the study
endpoints difficult. Although we performed extensive risk
adjustment to account for these vast differences in the base-
line characteristics, confounders that were not recorded
might have continued to influence our primary and second-
ary outcomes. For instance, we did not have reliable, vali-
dated measures of socioeconomic status included in our
current database. Furthermore, statin therapy might have
been a surrogate for greater health-seeking behavior in gen-
eral. The NL statin users were more likely to be concomi-
tantly treated with clopidogrel, aspirin, and b-blockers
than were the nonusers. Additionally, statins appeared toThe Journal of Thoracic and Carsignificantly reduce, not only cardiac, but also noncardiac,
mortality in our cohort, supporting this ‘‘healthy-user ef-
fect.’’ However, despite recording a history of hyperlipid-
emia within 6 months of the index surgery, data regarding
the LDL cholesterol levels (as a continuous variable) before
surgery were not available. Such data would have allowed
for more robust analysis of the relationship between LDL
cholesterol reduction and event rates after cardiac surgery.
Another major limitation of our study was that the precise
reasons behind withholding statin therapy in this patient
population were not explicitly determined. The baseline pa-
tient characteristics (eg, elevated liver enzymes) related to
these treatment differences might have influenced the short-
and long-term cardiovascular outcomes. Finally, our institu-
tional database did not include data detailing the specific
dosages, types of statins (high or low efficacy), or durations
of therapy. Our hypothesis-generating work warrants addi-
tional investigation into the role of statin therapy for pa-
tients with normal baseline lipid levels presenting for
cardiovascular surgery. Large prospective studies are war-
ranted to help establish guidelines for appropriate targets
for therapy (dosing, type, and duration of use) for a given
baseline risk factor profile.
Despite great strides in perioperative care and improve-
ments in surgical technique, patients undergoing cardiac
surgery remain at substantial risk of early and late cardio-
vascular complications. This risk is especially striking in
patients with underlying comorbid conditions and known
cardiac risk factors, including hyperlipidemia. Statin ther-
apy might help attenuate the excess risk conferred by
high LDL cholesterol before cardiac surgery. Thus, HL pa-
tients taking statins might have similar (or even better)
prognoses compared with untreated NL patients. Patients
undergoing cardiac surgery should not be categorically in-
cluded or excluded from the benefits of powerful lipid-
lowering therapy. Despite mounting evidence supporting
the use of statin therapy in the setting of cardiac surgery,
statins remain considerably underused in the perioperative
period.25 Our findings have important implications for
treatment targets, perioperative patient management, and
risk stratification in the setting of cardiac surgery. The re-
sults of the present study have changed our practice to
a more aggressive use of statins in cardiac surgery, regard-
less of the patients’ preoperative cholesterol levels. Future
studies will determine whether this change is warranted
for the entire cardiac surgery population.
We would like to thank Michael Yensel, Anna Huskin, and the
Bluhm Cardiovascular Institute Clinical Trials Unit for their
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Dr David A. Fullerton (Aurora, Colo). Dr Lee, I enjoyed your
presentation very much, and I think it is important that we in the
audience acknowledge that it is not necessarily easy to (a) collate
the information, the data on such a cohort of patients, and then (b)
try to drill down and actually make sense of it, so I think you and
your group are to be congratulated on that.
Having said that, I think it is very important, as you have done,
to acknowledge the limitations of such studies. It is a very hetero-
geneous group of patients. You appropriately acknowledge the
many recognized and unrecognized confounding variables that
may have influenced the data. Having said that, just as you accu-
rately pointed out, the prevailing literature strongly supports the
notion that there seems to be an association with statin usage
around the time of a variety of different types of cardiac operations
and favorable outcomes. That said, I wanted to invite you to spec-
ulate a little bit on how the mechanism of such an association
might be explored. For instance, I think it would be a pretty
straightforward matter to take blood or tissue samples seeking
evidence of proinflammatory stimulation or anti-inflammatory
effects of statins, that sort of thing. I was curious—have you and
your group discussed this? Have you embarked on this, or would
that be of interest to you?
Again, I enjoyed your talk very much and thank you.
Dr Lee. Thank you for those comments and the questions.
I agree. We have one of a few different ways that we are sorting
out where we go to next. Clearly we need to do this in a more
prospective fashion and we need to look a little bit better at the
patients who were not started preoperatively for 6 months but
were started postoperatively and what happens to them long-
term as well. So there are still some things within the data set
that we need to capture more effectively; however, in the next
step, we do need to look at troponins, CK MBs, and CRPs around
the time of surgery in the users versus nonusers, and do a much
more sophisticated analysis of that patient population. I think
what really needs to be done is a much bigger prospective study
on a wider scale. Again, and I appreciate your comments—this
is the beginning and it may or may not be real but I know I am tak-
ing an aspirin a day and that was based on an early study a long
time ago. Wemay evolve to the point where we start taking a statin
a day, too.
Dr Irving Kron (Charlottesville, Va). Dr Lee, I enjoyed your
talk. We have published similar data just a couple of years ago
and, in fact, we had proposed—as you all know, there is a network
at the NHLBI doing cardiovascular surgical research and this is
one study we proposed in valvular heart disease. I think it is
a real thing and there are data at least in animals, Dr. Fullerton,
that looks at these issues, so you have convincing data. Are you
going to have every valve patient that comes in started on a statin?
Dr Lee. We already do. The question is how to get them
6 months before. I think we need to do again is if this gets a little
more weight we need to not only present it at a forum like this. We
had an offshoot of this presentation that we presented at the ACC
but we need to help our cardiology colleagues look at this issue as
well.
Dr John C. Chen (Honolulu, Hawaii). As an extension of that,
how long in advance would you have them start on the statin prior
to surgery?gery c November 2010
Vaduganathan et al Acquired Cardiovascular DiseaseDr Lee. The answer is yes. [Laughter] I think realistically that is
what the trial would be for and as surgeons—I don’t know about
your practice but a lot of my practice is in-house, so I think at
time of diagnosis but if you really want to look at it, you look at
your valve practice. Take the valve people. You could probably
hold off at least 2 to 4 weeks on the valve and design it that way.
Otherwise, it actually probably is not very good because if you
have to wait too long for the valve population this kind of stuff
is not good. This won’t help them at all unless even that 2-month
window makes a difference and that is why we need to start with
a trial.
Dr Craig Baker (Los Angeles, Calif). Thank you for an excel-
lent presentation. As we heard a couple days ago, there is very
convincing evidence that children with congenital heart disease
are becoming a large growing population and we are increasingly
operating on teenagers and young adults with tetrology repairs,
putting in, as we heard, bioprosthetic valves. This may require a lit-
tle bit of speculation but what would be your advice in this young
population who are having new valves put in as many of them areThe Journal of Thoracic and Car
Delective and we would have time to start preoperative therapy. It is
not usually in an urgent setting. In fact, I was rounding last week
and one of our 25-year-olds who we did this procedure in and the
team had started them on statin therapy and we at rounds said, hey,
we don’t want to put this young patient on medication he may take
for the next 30 to 40 years. Could you offer any advice for this
particular patient population?
Dr Lee. As you know, the recommendation from the ACCHA
was to start it even in the teen population, which was a little contro-
versial, but we also have done an analysis of purely valve patients
looking at users, nonusers, stoppers, and starters. In fact, we found
a survival advantage for those patients who were put on statin
therapy and continued on it even when it was postoperative.
When patients stopped it for any reason whatsoever they had a sur-
vival disadvantage. Again, that’s cloudy. Who knows why they
stopped it? But at least it is our preliminary impression that, yes,
patients undergoing valve surgery, particularly with bioprosthetic
valves, should be getting statins. We need more literature to really
support that but that would be our practice in the current era.diovascular Surgery c Volume 140, Number 5 1027
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